Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Warrants

26 Nov 2018 07:00

RNS Number : 4097I
Mereo BioPharma Group plc
26 November 2018
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Issue of Warrants

 

 

London, 26 November 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, announced today the issue of warrants associated with the previously announced investment from the venture philanthropy arm of the Alpha-1 Foundation.

 

In accordance with the terms of the investment, the Company has issued warrants giving the Alpha-1 Foundation the right to subscribe to 41,286 shares at a price of £0.003 per share, currently equivalent to approximately 0.06% of the issued share capital of the Company. These warrants will be capable of exercise from completion of the Company's Phase 2 clinical study of MPH-966 (alvelestat) until 2 November 2028.

 

 

Enquiries:

 

Mereo BioPharma Group plc

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

Richard Jones, Chief Financial Officer

Cantor Fitzgerald Europe (Nominated Adviser and Broker)

+44 (0)20 7894 7000

Phil Davies

Will Goode

Rick Thompson

RBC Capital Markets (Joint Broker)

+44 (0)20 7653 4000

Rupert Walford

Jamil Miah

FTI Consulting (Public Relations Adviser)

+44 (0)20 3727 1000

Simon Conway

Brett Pollard

Burns McClellan (US Public Relations Advisor to Mereo Biopharma)

+01 (0) 212 213 0006

Lisa Burns

Ami Bavishi

 

 

About Mereo BioPharma

 

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio currently consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta ("OI"); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency ("AATD"); BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, ("AECOPD"); and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for all four of the product candidates and has previously announced positive top-line results from two of its clinical trials: a Phase 2 trial with BCT-197 in December 2017 and a Phase 2b dose-ranging study with BGS-649 in March 2018. The Company recently announced that the first patient has been dosed in its Phase 2 clinical study of MPH-966 for the treatment of AATD. The Company also recently announced completion of enrolment with 112 adult patients in the Phase 2b dose ranging study of BPS-804 in osteogenesis imperfecta.

 

About The Alpha-1 Project

 

Mission statement: The Alpha-1 Project works with patients, academia, pharmaceutical and biotech companies, and public health organizations in the relentless pursuit of cures and therapies for COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency. For more information, visit www.thealpha-1project.com. The Alpha-1 Project is a wholly-owned for-profit subsidiary of the Alpha-1 Foundation. For more information on the Foundation, visit www.alpha1.org.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEDMMZMGKFGRZZ
Date   Source Headline
5th Aug 20085:26 pmRNSFinal Results
5th Aug 20088:31 amRNSFinal Results
26th Jun 20081:32 pmRNSCorrection to Agreements
6th Jun 20087:00 amRNSNew London Store Opening
5th Jun 20087:00 amRNSNew licence agreements
28th May 20083:34 pmRNSHolding(s) in Company
2nd May 200811:06 amRNSHolding(s) in Company
24th Apr 20084:12 pmRNSHolding(s) in Company
20th Mar 20085:05 pmRNSHolding(s) in Company
10th Mar 200812:08 pmRNSFinance Director Appointment
4th Mar 20083:33 pmRNSHolding(s) in Company
18th Feb 20087:00 amRNSDirectorate Change
15th Feb 20084:46 pmRNSHolding(s) in Company
5th Feb 200811:17 amRNSHolding(s) in Company
1st Feb 20083:07 pmRNSInterim Management Statement
29th Jan 20085:49 pmRNSHolding(s) in Company
18th Jan 20087:01 amRNSSettlement of Ozwald Boateng
28th Nov 20079:45 amRNSNotification of Interest
21st Nov 20073:47 pmRNSDirector/PDMR Shareholding
20th Nov 20071:53 pmRNSDirector/PDMR Shareholding
20th Nov 200711:31 amRNSResult of EGM
19th Nov 20075:14 pmRNSDividend Payment
19th Nov 20077:01 amRNSInterim Results
16th Nov 200711:30 amRNSHolding(s) in Company
13th Nov 20075:07 pmRNSNotice of Interim Results
11th Oct 20074:07 pmRNSCirc to Shareholders
14th Sep 20079:46 amRNSHolding(s) in Company
7th Sep 20077:00 amRNSNew Licence and Distribution
6th Sep 200712:14 pmRNSResult of AGM
6th Sep 20077:00 amRNSAGM Statement
31st Aug 20077:01 amRNSTransaction in Own Shares
30th Aug 20077:01 amRNSTransaction in Own Shares
23rd Aug 20071:54 pmRNSAnnual Report and Accounts
15th Aug 20071:20 pmRNSHolding(s) in Company
8th Aug 20077:00 amRNSInterim Management Statement
8th Aug 20077:00 amRNSBoard Appointment
26th Jul 20077:00 amRNSDirectorate Change
18th Jul 20078:00 amRNSDirector/PDMR Shareholding
16th Jul 20071:30 pmRNSHolding(s) in Company
5th Jul 20077:46 amRNSNew Distribution Agreement
28th Jun 20077:04 amRNSFinal Results
12th Jun 20077:00 amRNSNew Contract Win
4th Jun 20073:58 pmRNSHolding(s) in Company
31st May 20079:10 amRNSNotice of Results
24th May 200711:11 amRNSHolding(s) in Company
11th May 20074:49 pmRNSHolding(s) in Company
27th Apr 20077:01 amRNSNew Licence Agreement
23rd Mar 200712:46 pmRNSHolding(s) in Company
12th Mar 20077:04 amRNSContract Win
7th Mar 20074:11 pmRNSResolutions Passed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.